Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DiaMedica, a drug discovery and development company, has received a contribution of up to $492,316 in addition to both technical and business oriented advisory services from the National Research Council of Canada Industrial Research Assistance Program.
Subscribe to our email newsletter
The funding will be applied to the company’s DM-99 development program for the treatment of type 2 diabetes.
Reggie Bowerman, president and CEO of DiaMedica, said: “We are very pleased that the National Research Council of Canada Industrial Research Assistance Program has seen the merit in and chosen to support the development of this exciting technology.
“DiaMedica has previously announced encouraging preclinical and proof-of-concept clinical trial results with DM-99 and we will use this funding to further advance this important development program.”